Optimal Medicine Inc. Renamed IXICO Technologies Inc.

May 18, 2016
News

IXICO plc, the brain health company, is pleased to announce that Optimal Medicine Inc. has been renamed IXICO Technologies Inc. with immediate effect.


A key part of the East Coast based Optimal Medicine acquisition on 8 December 2015 was to bring [US] infrastructure and IT Healthcare expertise.  The renaming of the company to IXICO Technologies Inc is a final and important step in the integration of Optimal Medicine within the enlarged IXICO Group and reflects the Company’s plans to build the US presence under the leadership of Kenneth Tubman, who joined the Group management team as VP of Healthcare Technology.

The IXICO Technologies Inc. team are focused on developing and supporting IXICO's mehealth® products and associated services in clinical decision support.  They will:

  • Play a key role in supporting the mehealth® for ADHD technology pilot with the American Academy of Pediatrics (“AAP”) as part of its Chapter Quality Network improvement program (see full press release here);

  • Lead development of IXICO's MyBrainBook® digital platform for patients with dementia as part of a number of NHS Testbed pilots (see full press release here); and 

  • Lead the expansion of the mehealth® product into monitoring patients with dementia and the incorporation of wearable sensor technologies as part of IXICO's Cygnus study (see full press release here).  

The team will play a key role in IXICO's continued strategy to develop, deploy and support a broad range of digital products that meet the needs of pharmaceutical companies developing and providing treatments for CNS diseases.


Professor Derek Hill, IXICO Chief Executive Officer, commented:

“The seamless integration of Optimal Medicine into the enlarged IXICO Group enhances the already close relationship between Ken’s team in the US and those in the UK and provides international expertise for our pharmaceutical partners across the globe.  The US presence will further the development of the mehealth clinical decision support tools and will play an increasingly important role in the product development across IXICO’s digital platform.”

 



Enquiries:

IXICO plc    +44 20 3763 7499
Derek Hill, CEO    
Susan Lowther, CFO    
    
FTI Consulting Limited (Investor Relations)
    +44 20 3727 1000
Simon Conway / Mo Noonan / Matthew Moss    


Notes to Editors

About IXICO
IXICO’s innovative and proprietary digital healthcare technologies help those involved in researching and treating serious diseases to capture and analyse clinical data to make rapid, informed decisions.  In clinical research this includes the phenotyping of patients, quantification of disease pathology and measurement of patient outcomes.  In clinical practice the mobile health and digital decision support technologies aid diagnosis, patient engagement and monitoring. IXICO is also collaborating with partners to develop companion digital health products targeted at improving patient outcomes.

The Company’s brain health focus includes Alzheimer’s disease, Huntington’s disease, multiple sclerosis, Parkinson’s disease, behavioural health, child and adolescent mental health.

More information is available on WWW.IXICO.COM.

About mehealth® 
mehealth® for ADHD is an evidence-based, comprehensive, and easy-to-use online tool.  The mehealth platform integrates web-based and mobile technologies for clinicians and patients, allowing care to be initiated and adapted according to the patients’ unique profile and evolving needs.  The software has been used in the care of over 12,000 children across the US and has been shown in a randomized trial to improve concordance with the AAP’s ADHD clinical guidelines.

http://pediatrics.aappublications.org/content/early/2011/10/14/peds.2011-0872].

More information is available on www.mehealth.com.

About MyBrainBook®
MyBrainBook® has been developed by IXICO as a new way of providing the best care to people with dementia.  MyBrainBook is a digital hub which gives people with dementia and their carers the ability to build a personal profile and action plan with information they provide about the important aspects of their life.  Restricted access is available to health and social care workers to ensure the appropriate support can be provided when needed.

More information is available on WWW.MYBRAINBOOK.COM.

About the Cygnus Project 
Cygnus is a two year project funded by Innovate UK and brings together four Mental Health Trusts in the North of England, the Northern Health Science Alliance (NHSA), IXICO and the International Consortium for Health Outcomes Measures (ICHOM).  The project is the first implementation of the recently published ICHOM dementia standard dataset.

The Mental Health Trusts and lead investigators participating in the project are:

  • Manchester Health and Social Care Trust / University of Manchester (Dr. Iracema Leroi) 

  • Mersey Care (Dr. Deep Majumdar)

  • Tee, Esk and Wear Valleys NHS Foundation Trust (Dr. Gemma Murphy)

  • Northumberland, Tyne and Wear NHS Foundation Trust (Dr. Andrew Byrne)

The project aims to enrol 500 participants: patients referred to Memory Assessment Services at the participant Trusts with suspected dementia and their carers.  Key objectives of the Cygnus study are:

  • To evaluate the feasibility of web-based, mobile and wearable technologies as a means to collect high quality and actionable data from patients and their care givers; 

  • Linking these measurements to data about outcomes and episodes of care; 

  • To provide a well-characterised population who have consented to contact about future evaluation of technologies and interventions that might benefit patients and carers.

More information is available on WWW.ECYGNUS.COM.